Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Breast malignant tumors are a serious threat to women's health, and the current treatment for breast malignant tumors is still dominated by surgery, but the problems faced by patients after surgery such as edema and tumor recurrence are still relatively common, and the high recurrence rate and the occurrence of postoperative complications are closely related to the removal of metastatic lymph nodes during surgery. Therefore, accurate assessment of sentinel lymph node (SLN) metastases is essential to determine the extent of axillary lymph node dissection (ALND) and minimize complications. In this study, we developed a new technique that can rapidly distinguish between metastatic lymph nodes and normal sentinel lymph nodes (SLNs) in breast cancer patients. Briefly, fresh tissue is incubated with the probe and imaged immediately after intraoperative sentinel lymph node resection to identify the metastatic status of SLN. The accuracy of fluorescence imaging is confirmed by pathological diagnosis.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 75 lat
- •Guz piersi, który można usunąć chirurgicznie
- •Pacjenci z rakiem piersi przygotowani do biopsji węzła wartowniczego lub usunięcia węzłów chłonnych
- •Dobry stan zdrowia do przeprowadzenia operacji
- •Zdolność do wyrażenia świadomej zgody na udział w badaniu
✗ Disqualifies
- •Niemożność uczestniczenia w procesie wyrażania zgody
- •Przeciwwskazania do operacji, takie jak poważne choroby serca i płuc lub zaburzenia krzepnięcia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 4, 2025
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Yunnan Cancer Hospital, Kunming, Yunnan 650118
Kunming, China
Trial contact
Junhong Chen, Postgraduate
Weiling Chen, Doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.